Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 102
Filter
1.
J Ethnopharmacol ; 270: 113848, 2021 Apr 24.
Article in English | MEDLINE | ID: mdl-33485977

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Cinobufacini is extracted from the skins and parotid venom glands of the toad for treating symptoms like swelling and pain in ancient times. Nowadays, cinobifucini injection has also achieved satisfactory therapeutic effects on hepatocellular carcinoma (HCC) in China. AIM OF THE STUDY: Our previous work found that bufothionine, an alkaloid abundant in cinobufacini injection, induced mitochondria-mediated apoptosis. In this work, the underlying effects of bufothionine on autophagy in HCC and its possible dependent pathway were investigated. METHODS: CCK-8 and Hoechst staining assays were performed to verify effects of drugs on proliferation and apoptosis of SMMC7721 cell. H22-tumor-bearing mice model was established by inoculating ascites fluid. HE staining was used to observe pathological changes in liver and tumor tissues. ELISA and Western blot experiments were conducted to investigate IL-6/JAK2/STAT3 signaling pathway. The effects of drugs on expressions of autophagic relative proteins were investigated by Western blot in vitro and in vivo. RESULTS: In vitro, CCK-8 and Hoechst staining assays showed that bufothionine inhibited SMMC7721 cell proliferation and promoted apoptosis at 100 µM. In vivo, bufothionine relieved symptoms of H22-tumor-bearing mice and exerted anti-inflammation activity. ELISA and Western blot demonstrated that bufothionine significantly reduced serum IL-6 concentration, suppressed p-Stat3tyr705, p-Stat3ser727 and Jak2 expressions in tumor tissues and upregulated Atg5, Atg7 and LC3Ⅱ expressions in SMMC7721 cell and H22 tumor. CONCLUSION: This is the first report showing that bufothionine might induce autophagy in HCC by inhibiting JAK2/STAT3 pathway, presenting a possible anti-cancer mechanism of bufothionine in cinobufacini injection.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Autophagy/drug effects , Bufanolides/pharmacology , Indole Alkaloids/pharmacology , Liver Neoplasms, Experimental/drug therapy , Neoplasms/pathology , Quinolinium Compounds/pharmacology , Signal Transduction/drug effects , Animals , Antineoplastic Agents, Phytogenic/therapeutic use , Apoptosis/drug effects , Bufanolides/chemistry , Bufanolides/therapeutic use , Cell Line, Tumor , Cell Proliferation/drug effects , Humans , Indole Alkaloids/therapeutic use , Interleukin-6/antagonists & inhibitors , Janus Kinase 2/antagonists & inhibitors , Janus Kinase 2/metabolism , Liver Neoplasms, Experimental/metabolism , Liver Neoplasms, Experimental/pathology , Male , Mice , Neoplasms/metabolism , Quinolinium Compounds/therapeutic use , STAT3 Transcription Factor/antagonists & inhibitors , STAT3 Transcription Factor/metabolism
2.
Rev Bras Parasitol Vet ; 28(2): 320-324, 2019 Jun 06.
Article in English | MEDLINE | ID: mdl-31188944

ABSTRACT

Trypanosomiasis caused by Trypanosoma evansi can seriously affect both domestic and wild animals. This article reports on an outbreak of canine trypanosomiasis on a farm in the Pantanal region of Brazil. The farm had 38 dogs, 20 of which died before receiving veterinary care. The remaining 18 dogs were underwent anamnesisn, clinical examination, hematological and biochemical evaluations. Blood smears and PCR analysis were performed for the diagnosis. The treatment protocols used according to the clinical recovery or parasitological cure of the dogs, using diminazene diaceturate, isometamidium chloride or quinapyramine sulfate. Post-treatment parasitological evaluation was performed by the microhematocrit technique. 7/18 dogs were PCR positive for T. evansi (confirmed by sequencing). There was clinical findings, which were consistent with both the acute and chronic stages of the disease in dogs. The infected dogs all exhibited at least one clinical sign of the disease. The hematological findings were compatible with trypanosomiasis, highlighting the hypochromic microcytic anemia as the main outcome. No treatment protocol was fully effective and the prolonged use of diminazene diaceturate caused the death of an animal. The trypanosomiasis can cause high rates of morbidity and mortality in dogs and difficulty in establishment an effective and safe therapeutic protocol.


Subject(s)
Diminazene/analogs & derivatives , Dog Diseases/diagnosis , Phenanthridines/therapeutic use , Quinolinium Compounds/therapeutic use , Trypanosomiasis/diagnosis , Animals , Brazil/epidemiology , Diminazene/therapeutic use , Disease Outbreaks , Dog Diseases/drug therapy , Dog Diseases/epidemiology , Dogs , Female , Male , Polymerase Chain Reaction/veterinary , Trypanosomiasis/drug therapy , Trypanosomiasis/epidemiology
3.
Rev. bras. parasitol. vet ; 28(2): 320-324, Apr.-June 2019. graf
Article in English | LILACS | ID: biblio-1042503

ABSTRACT

Abstract Trypanosomiasis caused by Trypanosoma evansi can seriously affect both domestic and wild animals. This article reports on an outbreak of canine trypanosomiasis on a farm in the Pantanal region of Brazil. The farm had 38 dogs, 20 of which died before receiving veterinary care. The remaining 18 dogs were underwent anamnesisn, clinical examination, hematological and biochemical evaluations. Blood smears and PCR analysis were performed for the diagnosis. The treatment protocols used according to the clinical recovery or parasitological cure of the dogs, using diminazene diaceturate, isometamidium chloride or quinapyramine sulfate. Post-treatment parasitological evaluation was performed by the microhematocrit technique. 7/18 dogs were PCR positive for T. evansi (confirmed by sequencing). There was clinical findings, which were consistent with both the acute and chronic stages of the disease in dogs. The infected dogs all exhibited at least one clinical sign of the disease. The hematological findings were compatible with trypanosomiasis, highlighting the hypochromic microcytic anemia as the main outcome. No treatment protocol was fully effective and the prolonged use of diminazene diaceturate caused the death of an animal. The trypanosomiasis can cause high rates of morbidity and mortality in dogs and difficulty in establishment an effective and safe therapeutic protocol.


Resumo A tripanossomíase causada por Trypanosoma evansi pode acometer gravemente os animais domésticos e selvagens. Este artigo relata um surto de tripanossomíase canina em uma fazenda na região do Pantanal, Brasil. Na fazenda havia 38 cães, 20 dos quais morreram antes de receber cuidados veterinários. Os 18 cães restantes foram submetidos a anamnese, exame clínico, avaliação hematológica e bioquímica. Esfregaços de sangue e análise da PCR foram realizados para o diagnóstico. Os protocolos de tratamento foram utilizados de acordo com a recuperação clínica ou cura parasitológica dos cães, utilizando diaceturato de diminazeno, cloreto de isometamídio ou sulfato de quinapiramina. A avaliação parasitológica pós-tratamento foi realizada pela técnica de microhematócrito. 7/18 cães foram PCR positivos para T. evansi (confirmado por sequenciamento). Os achados clínicos encontrados, foram consistentes com os estágios agudo e crônico da doença em cães. Todos os cães infectados exibiram pelo menos um sinal clínico da doença. Os achados hematológicos foram compatíveis com a tripanossomíase, destacando a anemia microcítica hipocrômica como principal consequência. Nenhum protocolo de tratamento foi totalmente eficaz e o uso prolongado de diaceturato de diminazeno causou a morte de um animal. A tripanossomíase pode causar altas taxas de morbidade e mortalidade em cães e dificultar o estabelecimento de um protocolo terapêutico eficaz e seguro.


Subject(s)
Humans , Male , Female , Dogs , Phenanthridines/therapeutic use , Quinolinium Compounds/therapeutic use , Trypanosomiasis/diagnosis , Diminazene/analogs & derivatives , Dog Diseases/diagnosis , Trypanosomiasis/therapy , Trypanosomiasis/epidemiology , Brazil/epidemiology , Polymerase Chain Reaction/veterinary , Disease Outbreaks , Diminazene/therapeutic use , Dog Diseases/drug therapy , Dog Diseases/epidemiology
4.
Biomed Pharmacother ; 80: 145-150, 2016 May.
Article in English | MEDLINE | ID: mdl-27133051

ABSTRACT

Tumour growth is closely related to the development of new blood vessels to supply oxygen and nutrients to cancer cells. Without the neovascular formation, tumour volumes cannot increase and undergo metastasis. Antiangiogenesis is one of the most promising approaches for antitumour therapy. The exploration of new antiangiogenic agents would be helpful in antitumour therapy. Quinoline is an aromatic nitrogen compound characterized by a double-ring structure which exhibits a benzene ring fused to pyridine at two adjacent carbon atoms. The high stability of quinoline makes it preferable in a variety of therapeutic and pharmaceutical applications, including antitumour treatment. This work is to examine the potential antiangiogenic activity of the synthetic compound 2-Formyl-8-hydroxy-quinolinium chloride. We found that 2-Formyl-8-hydroxy-quinolinium chloride could inhibit the growth of human umbilical vein endothelial cells in vitro. Using the diethylnitrosamine-induced hepatocarcinogenesis model, 2-Formyl-8-hydroxy-quinolinium chloride showed strong antiangiogenic activity. Furthermore, 2-Formyl-8-hydroxy-quinolinium chloride could inhibit the growth of large Hep3B xenografted tumour from the nude mice. We assume that 2-Formyl-8-hydroxy-quinolinium chloride could be a potential antiangiogenic and antitumour agent and it is worthwhile to further study its underlying working mechanism.


Subject(s)
Angiogenesis Inhibitors/pharmacology , Hydroxyquinolines/pharmacology , Quinolinium Compounds/pharmacology , Angiogenesis Inhibitors/chemistry , Angiogenesis Inhibitors/therapeutic use , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Carcinogenesis/pathology , Carcinoma, Hepatocellular/blood supply , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/pathology , Cell Death/drug effects , Cell Proliferation/drug effects , Diethylnitrosamine , Human Umbilical Vein Endothelial Cells/drug effects , Humans , Hydroxyquinolines/chemistry , Hydroxyquinolines/therapeutic use , Liver Neoplasms/blood supply , Liver Neoplasms/drug therapy , Liver Neoplasms/pathology , Mice, Inbred C57BL , Mice, Nude , Quinolinium Compounds/chemistry , Quinolinium Compounds/therapeutic use , Tumor Burden/drug effects , Xenograft Model Antitumor Assays
5.
Vet Parasitol ; 223: 77-87, 2016 Jun 15.
Article in English | MEDLINE | ID: mdl-27198781

ABSTRACT

Trypanosomosis (Surra) is an economically important disease caused by Trypanosoma evansi which is an extracellular parasite present in the plasma, tissues and other body fluids of a wide range of hosts including domesticated animals. Currently, serological reports are based on detection of antibodies by ELISA using whole cell lysate (WCL) antigen, which has a limitation of persistence of anti-trypanosomal antibodies after successful treatment of the disease. Moreover, it has some ethical issues also like requirement of mice for in vivo maintenance of parasite for preparing the antigen. Therefore, in the present study, an attempt was made to evaluate the in vitro production of recombinant heat shock protein 70 (HSP70) for detection of antibodies in experimentally infected ponies. The amino acid sequence analysis of HSP70 revealed that N-terminal region of the protein was highly conserved while the C-terminal region was most divergent. The four different regions of HSP70 protein viz. HSP-1, HSP-2, HSP-3 and HSP-4 were cloned and expressed, among which HSP-1 (N-terminal region) & HSP-2 (C-terminal region) were truncated while HSP-3 & HSP-4 were complete C-terminal proteins. The recombinant fragments were probed with sequentially pooled experimental serum samples where antibodies were detected in these fragments from 10(th) day post infection till the termination of the experiment. Further, these recombinant fragments were also comparatively evaluated with WCL antigen in ELISA using experimental as well as field serum samples. It was observed that after successful treatment of infected ponies, there was a sharp fall in antibodies (within 90 days) when tested with recombinant HSP's fragments, while antibodies persisted even after 469 days when tested against WCL antigen. The sensitivity and specificity of all HSP70 fragments were also estimated from field serum samples with reference to WCL antigen ELISA. The HSP-1 showed minimum sensitivity (41.03%) among all the recombinant fragments. Among the C-terminal fragments, maximum sensitivity was observed with the HSP-2 (61.54%) while minimum was observed with HSP-4 (48.72%). The specificity increases for recombinant fragments from N-terminal to C-terminal region of protein and maximum specificity was observed with HSP-4 fragment (91.3%).


Subject(s)
HSP70 Heat-Shock Proteins , Horse Diseases/parasitology , Serologic Tests/veterinary , Trypanosomiasis/veterinary , Amino Acid Sequence , Animals , Cloning, Molecular , Female , Horse Diseases/diagnosis , Horse Diseases/drug therapy , Horses , Parasitemia/veterinary , Quinolinium Compounds/therapeutic use , Sensitivity and Specificity , Serologic Tests/methods , Trypanosomiasis/diagnosis , Trypanosomiasis/drug therapy , Trypanosomiasis/parasitology
6.
Exp Parasitol ; 165: 35-42, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26988923

ABSTRACT

A growing number of atypical human infections due to the livestock parasite Trypanosoma evansi, or to the rat parasite Trypanosoma lewisi, are reported in humans in Asia. In some cases, clinical evolutions request treatments, however, so far, there were very few attempts to control T. lewisi using trypanocidal drugs. In a study published elsewhere, the efficacy of human trypanocides is evaluated in laboratory rats, and it concludes that none of them is able to cure rats experimentally infected with T. lewisi. Control of T. lewisi in rat would be a step for identification of drugs against this parasite. In the present study, 4 veterinary drugs: diminazene aceturate, isometamidium chloride, melarsomine hydrochloride and quinapyramine sulfate and chloride, were evaluated at low and high doses, in intra-muscular injections to normal rats experimentally infected with a stock of T. lewisi from Thailand. None of these treatments being efficient, a trial was also made using melarsomine hydrochloride in T. evansi infected rats and in mixed T. lewisi and T. evansi infected rats, in order to demonstrate the efficacy of the drugs under the present protocol. T. evansi was cleared from the rat's blood the day after the treatment, while, T. lewisi remained unaffected until the end of the experiment. These observations clearly demonstrated the efficacy of melarsomine hydrochloride against T. evansi and its inefficacy against T. lewisi. In conclusion none of the veterinary drugs was efficient against this stock of T. lewisi. Other protocols using higher doses or other drugs and T. lewisi stocks should be investigated in further studies. The control of T. lewisi infection in Wistar rats, using veterinary trypanocidal drugs, remains so far unsuccessful.


Subject(s)
Trypanocidal Agents/therapeutic use , Trypanosoma lewisi , Trypanosomiasis/prevention & control , Veterinary Drugs/therapeutic use , Zoonoses , Animals , Arsenicals/pharmacology , Arsenicals/therapeutic use , Diminazene/analogs & derivatives , Diminazene/pharmacology , Diminazene/therapeutic use , Female , Humans , Mice , Parasitemia/drug therapy , Parasitemia/parasitology , Phenanthridines/pharmacology , Phenanthridines/therapeutic use , Quinolinium Compounds/pharmacology , Quinolinium Compounds/therapeutic use , Rats , Rats, Wistar , Triazines/pharmacology , Triazines/therapeutic use , Trypanocidal Agents/pharmacology , Trypanosoma lewisi/drug effects , Trypanosomiasis/drug therapy , Veterinary Drugs/pharmacology , Zoonoses/parasitology , Zoonoses/prevention & control
7.
J Biol Chem ; 291(9): 4356-73, 2016 Feb 26.
Article in English | MEDLINE | ID: mdl-26679998

ABSTRACT

The mitochondrial permeability transition pore is a recognized drug target for neurodegenerative conditions such as multiple sclerosis and for ischemia-reperfusion injury in the brain and heart. The peptidylprolyl isomerase, cyclophilin D (CypD, PPIF), is a positive regulator of the pore, and genetic down-regulation or knock-out improves outcomes in disease models. Current inhibitors of peptidylprolyl isomerases show no selectivity between the tightly conserved cyclophilin paralogs and exhibit significant off-target effects, immunosuppression, and toxicity. We therefore designed and synthesized a new mitochondrially targeted CypD inhibitor, JW47, using a quinolinium cation tethered to cyclosporine. X-ray analysis was used to validate the design concept, and biological evaluation revealed selective cellular inhibition of CypD and the permeability transition pore with reduced cellular toxicity compared with cyclosporine. In an experimental autoimmune encephalomyelitis disease model of neurodegeneration in multiple sclerosis, JW47 demonstrated significant protection of axons and improved motor assessments with minimal immunosuppression. These findings suggest that selective CypD inhibition may represent a viable therapeutic strategy for MS and identify quinolinium as a mitochondrial targeting group for in vivo use.


Subject(s)
Cerebral Cortex/drug effects , Cyclophilins/antagonists & inhibitors , Mitochondrial Membrane Transport Proteins/antagonists & inhibitors , Multiple Sclerosis/prevention & control , Neurons/drug effects , Neuroprotective Agents/therapeutic use , Quinolinium Compounds/therapeutic use , Amino Acid Substitution , Animals , Cell Proliferation/drug effects , Cells, Cultured , Cerebral Cortex/immunology , Cerebral Cortex/metabolism , Cerebral Cortex/pathology , Peptidyl-Prolyl Isomerase F , Cyclophilins/genetics , Cyclophilins/metabolism , Cyclosporins/adverse effects , Cyclosporins/chemical synthesis , Cyclosporins/pharmacology , Cyclosporins/therapeutic use , Hep G2 Cells , Humans , Liver/drug effects , Liver/metabolism , Male , Mice, Inbred Strains , Mice, Knockout , Mitochondrial Membrane Transport Proteins/genetics , Mitochondrial Membrane Transport Proteins/metabolism , Mitochondrial Permeability Transition Pore , Multiple Sclerosis/immunology , Multiple Sclerosis/metabolism , Multiple Sclerosis/pathology , Mutation , Neurons/immunology , Neurons/metabolism , Neurons/pathology , Neuroprotective Agents/adverse effects , Neuroprotective Agents/pharmacology , Peptides, Cyclic/adverse effects , Peptides, Cyclic/chemical synthesis , Peptides, Cyclic/pharmacology , Peptides, Cyclic/therapeutic use , Quinolinium Compounds/adverse effects , Quinolinium Compounds/chemical synthesis , Quinolinium Compounds/pharmacology , Random Allocation , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , T-Lymphocytes/drug effects , T-Lymphocytes/pathology
8.
Phytomedicine ; 21(6): 877-82, 2014 May 15.
Article in English | MEDLINE | ID: mdl-24680618

ABSTRACT

The quinolinium chloride salt of 8-hydroxyqinolinecarbaldehyde (2-Formyl-8-hydroxy-quinolinium chloride) was prepared as Galipea longiflora alkaloid analogue and its anticancer activity was evaluated both in vitro and in vivo. This chloride salt was found to show certain degree of selectivity between hepatoma cells and normal hepatocytes in vitro. Athymic nude mice Hep3B xenograft model further demonstrated that this 2-Formyl-8-hydroxy-quinolinium chloride could execute strong anti-tumour activity with the identification of extensive necrotic feature from the tumour xenograft and limited adverse toxicological effect.


Subject(s)
Alkaloids/therapeutic use , Antineoplastic Agents, Phytogenic/therapeutic use , Carcinoma, Hepatocellular/drug therapy , Phytotherapy , Plant Extracts/therapeutic use , Quinolinium Compounds/therapeutic use , Rutaceae/chemistry , Alkaloids/pharmacokinetics , Alkaloids/pharmacology , Animals , Antineoplastic Agents, Phytogenic/pharmacokinetics , Antineoplastic Agents, Phytogenic/pharmacology , Chlorides/pharmacokinetics , Chlorides/pharmacology , Chlorides/therapeutic use , Hepatocytes/drug effects , Heterografts , In Vitro Techniques , Mice, Inbred C57BL , Mice, Nude , Necrosis , Plant Extracts/pharmacokinetics , Plant Extracts/pharmacology , Quinolinium Compounds/pharmacokinetics , Quinolinium Compounds/pharmacology , Salts
9.
Curr Opin Oncol ; 26(2): 237-44, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24441505

ABSTRACT

PURPOSE OF REVIEW: The use of agents which exhibit the ability to potently activate the innate immune response has gained significant interest as therapeutics to treat cancer. We will review the history and the current applications of these agents to treat skin cancer and cutaneous T-cell lymphoma. RECENT FINDINGS: Particular attention has been focused upon Toll-like receptor (TLR) agonists, including imidazoquinolines, which can trigger TLR 7 and TLR 8, and cytosine-phosphate-guanine (CpG) oligodeoxynucleotides, which activate TLR 9-expressing cells. Imiquimod, a TLR 7 agonist, has been found to be efficacious for basal cell and squamous cell cancers, as well as cutaneous T-cell lymphoma and lentigo maligna melanoma. CpGs have demonstrated efficacy for cutaneous T-cell lymphoma. Additional more potent compounds, including resiquimod, are presently in clinical trials for several types of skin cancers. SUMMARY: TLR agonists that can activate the innate immune response have been used to treat a variety of skin cancers including basal cell cancer, squamous cell cancer, lentigo maligna melanoma and cutaneous T-cell lymphoma. Significant clinical efficacy has been observed for all of these conditions. It is anticipated that additional members of the TLR agonist family will be available in the clinic for the future treatment of skin cancers as well as other malignancies.


Subject(s)
Lymphoma, T-Cell, Cutaneous/drug therapy , Skin Neoplasms/drug therapy , Toll-Like Receptors/agonists , Aminoquinolines/therapeutic use , Humans , Imiquimod , Lymphoma, T-Cell, Cutaneous/immunology , Lymphoma, T-Cell, Cutaneous/metabolism , Oligodeoxyribonucleotides/therapeutic use , Quinolinium Compounds/therapeutic use , Skin Neoplasms/immunology , Skin Neoplasms/metabolism , Toll-Like Receptor 7/agonists , Toll-Like Receptor 7/immunology , Toll-Like Receptor 7/metabolism , Toll-Like Receptor 8/agonists , Toll-Like Receptor 8/immunology , Toll-Like Receptor 8/metabolism , Toll-Like Receptor 9/agonists , Toll-Like Receptor 9/immunology , Toll-Like Receptor 9/metabolism , Toll-Like Receptors/immunology , Toll-Like Receptors/metabolism
10.
Trop Anim Health Prod ; 46(2): 371-7, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24197687

ABSTRACT

Trypanosoma evansi infection typically produces wasting disease, but it can also develop into a neurological or meningoencephalitis form in equids. Trypanosomiasis in horses was treated with quinapyramine sulfate, and all the 14 infected animals were recovered clinically. After clinical recovery, four animals developed a neurological form of the disease at various intervals. Two of these animals treated with diminazene aceturate recovered temporarily. Repeated attempts failed to find the parasite in the blood or the cerebrospinal fluid (CSF), but all of the animals were positive in enzyme-linked immunosorbent assay. The calculation of the antibody index (AI) in the serum and the CSF and polymerase chain reaction (PCR) analysis of the CSF and brain tissue were carried out to confirm the neuro-infection. We found PCR and AI analyses of the CSF to be useful tools in the diagnosis of the neurological form of trypanosomiasis when the organism cannot be found in the blood or CSF. The increased albumin quotient is indicative of barrier leakage due to neuroinflammation. The biochemical changes in the CSF due to nervous system trypanosomiasis include increases in the albumin quotient, total protein, and urea nitrogen. It seems to be the first report on relapse of the nervous form of trypanosomiasis in equids even after quinapyramine treatment in endemic areas.


Subject(s)
Blood-Brain Barrier , Central Nervous System Infections/veterinary , Horse Diseases/parasitology , Quinolinium Compounds/therapeutic use , Trypanosoma/isolation & purification , Trypanosomiasis/veterinary , Animals , Central Nervous System Infections/epidemiology , Central Nervous System Infections/parasitology , Diminazene/analogs & derivatives , Diminazene/therapeutic use , Disease Outbreaks/veterinary , Enzyme-Linked Immunosorbent Assay/veterinary , Horse Diseases/pathology , Horses , India/epidemiology , Trypanocidal Agents/therapeutic use , Trypanosoma/classification , Trypanosomiasis/parasitology , Trypanosomiasis/pathology
11.
Vet Parasitol ; 180(3-4): 349-53, 2011 Aug 25.
Article in English | MEDLINE | ID: mdl-21514732

ABSTRACT

Oxidant/antioxidant equilibrium disturbance has already been reported in trypanosome infections by several authors. The present study was aimed to explore the possible oxidant/antioxidant disturbance in surra of naturally infected horses before and after treatment. Fifteen naturally infected horses were chosen to analyse erythrocytic indices, platelet counts, lipid peroxides (LPO), nitric oxide (NO), reduced glutathione (GSH), superoxide dismutase (SOD) and catalase (CAT) while six healthy animals acted as control. There was a highly significant (P<0.001) reduction in red blood cell (RBC) count, haemoglobin (Hb), packed cell volume (PCV) and platelet levels and a significant reduction in mean corpuscular haemoglobin concentration (MCHC) (P<0.05) was noticed. A highly significant increase in NO (P<0.001), a significant increase in LPO (P<0.05) and a significant decrease in GSH, SOD and CAT (P<0.05) were found. A negative correlation of RBC count with LPO (r=-0.844) and nitrate (r=-0.702) while a positive correlation with GSH (r=0.489), SOD (r=0.580) and CAT (r=0.689) was observed. All the animals were treated with Quinapyramine sulphate (3mg/kg s.c.) only once. Nine animals recovered completely without any side effects. The recovered animals were monitored and samples were collected every seven days for up to 21 days and parameters were analysed. After treatment, a significant increase in haematological parameters was noticed whereas the oxidative indices varied without any statistical significance. To conclude, the increase in oxidant parameters and decrease in antioxidant enzymes in infected horses indicates the disturbance of oxidant/antioxidant indices. There was a significant increase in post therapy haematological values, while the oxidant/antioxidant indices changed insignificantly indicating that antioxidants might be supplemented in the therapeutic regimen.


Subject(s)
Antioxidants/metabolism , Horse Diseases/parasitology , Oxidants/blood , Trypanosoma/classification , Trypanosomiasis/veterinary , Anemia/veterinary , Animals , Horse Diseases/blood , Horse Diseases/metabolism , Horses , Oxidants/metabolism , Oxidative Stress , Quinolinium Compounds/therapeutic use , Trypanocidal Agents/therapeutic use , Trypanosomiasis/blood , Trypanosomiasis/drug therapy , Trypanosomiasis/metabolism
12.
Bioorg Med Chem Lett ; 21(8): 2505-9, 2011 Apr 15.
Article in English | MEDLINE | ID: mdl-21397501

ABSTRACT

This paper describes the preparation and in vitro evaluation of 18 newly prepared bis-quinolinium inhibitors on human recombinant acetylcholinesterase (AChE) and human plasmatic butyrylcholinesterase (BChE). Their inhibitory (IC(50)) and was compared to the chosen standards ambenonium dichloride, edrophonium chloride, BW284c51 and ethopropazine hydrochloride. One novel compound was found to be a promising inhibitor of hAChE (in nM range) and was better than edrophonium chloride or BW284c51, but was worse than ambenonium chloride. This compound also showed selectivity towards hAChE and it was confirmed as a non-competitive inhibitor of hAChE by kinetic analysis. A molecular modelling study further confirmed its binding to the peripheral active site of hAChE via apparent π-π or π-cationic interactions.


Subject(s)
Acetylcholinesterase/chemistry , Butyrylcholinesterase/chemistry , Cholinesterase Inhibitors/chemistry , Myasthenia Gravis/drug therapy , Quinolinium Compounds/chemistry , Acetylcholinesterase/genetics , Acetylcholinesterase/metabolism , Ambenonium Chloride/chemistry , Ambenonium Chloride/pharmacology , Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide/chemistry , Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide/pharmacology , Binding Sites , Butyrylcholinesterase/genetics , Butyrylcholinesterase/metabolism , Cholinesterase Inhibitors/pharmacology , Cholinesterase Inhibitors/therapeutic use , Edrophonium/chemistry , Edrophonium/pharmacology , Humans , Kinetics , Molecular Dynamics Simulation , Protein Binding , Quinolinium Compounds/pharmacology , Quinolinium Compounds/therapeutic use , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Structure-Activity Relationship
13.
J Cardiovasc Pharmacol ; 57(6): 672-81, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21394037

ABSTRACT

Atrial fibrillation (AF) is associated with increased morbidity and is in addition the most prevalent cardiac arrhythmia. Compounds used in pharmacological treatment has traditionally been divided into Na(+) channel inhibitors, ß-blockers, K(+) channel inhibitors, and Ca(2+) channel inhibitors, whereas newer multichannel blockers such as amiodarone and ranolazine have been introduced later. This study was devoted to the evaluation of an acute pacing-induced in vivo model of AF in rats. Antiarrhythmic effects of well-known compounds such as lidocaine, dofetilide, and ranolazine were confirmed in this model. In addition, antiarrhythmic effects of different inhibitors of Ca(2+)-activated small conductance K(+) (SK) channels were demonstrated. Intravenous application of 5 mg/kg of the negative SK channel modulator NS8593 reduced AF duration by 64.5%, and the lowest significantly effective dose was 1.5 mg/kg. A dose-effect relationship was established based on 6 different dose groups. Furthermore, it was demonstrated that the antiarrhythmic effect of NS8593 and other tested drugs was associated with an increase in atrial effective refractory period. The functional role of SK channels was confirmed by 2 other SK channel inhibitors, UCL1684 and apamin, thereby confirming the hypothesis that these channels might constitute a new promising target for antiarrhythmic treatment.


Subject(s)
Anti-Arrhythmia Agents/therapeutic use , Atrial Fibrillation/prevention & control , Cardiac Pacing, Artificial/adverse effects , Potassium Channel Blockers/therapeutic use , Small-Conductance Calcium-Activated Potassium Channels/antagonists & inhibitors , 1-Naphthylamine/administration & dosage , 1-Naphthylamine/analogs & derivatives , 1-Naphthylamine/therapeutic use , Alkanes/therapeutic use , Anesthesia , Animals , Anti-Arrhythmia Agents/administration & dosage , Apamin/therapeutic use , Atrial Fibrillation/drug therapy , Atrial Fibrillation/etiology , Disease Models, Animal , Dose-Response Relationship, Drug , Insect Proteins/therapeutic use , Male , Molecular Targeted Therapy , Potassium Channel Blockers/administration & dosage , Quinolinium Compounds/therapeutic use , Random Allocation , Rats , Rats, Sprague-Dawley , Reaction Time/drug effects , Time Factors
14.
Vet Parasitol ; 162(3-4): 214-20, 2009 Jun 10.
Article in English | MEDLINE | ID: mdl-19372008

ABSTRACT

An outbreak of trypanosomosis was observed for the first time in metropolitan France in October 2006, when five camels were proved to be infected by Trypanosoma evansi using parasitological methods. The parasite was isolated and used to produce a soluble antigen for antibody-enzyme linked immunosorbent assay (ELISA) in a protocol derived from a method previously developed for sheep and humans but using protein A conjugate. The animals were treated on three instances, alternatively with melarsomine hydrochloride and quinapyramine and followed up on a monthly basis for 2 years with various diagnostic techniques including parasitological, serological and DNA-based methods. Initially, five animals were detected as being positive using ELISA with 83.3% concordance to parasitological tests. Immediately after the first treatment, parasites and DNA disappeared in all animals; antibody levels decreased regularly until ELISA became negative 3-4 months later. Ten months after the first treatment, parasites and antibodies were detected again in one of the camels previously found to be infected. A retrospective study indicated that the weight of this animal had been underestimated; consequently, it had received underdosages of both trypanocides. However, since hypotheses of re-infection or relapse could not be fully substantiated, it is not known whether the ELISA results for this animal were true- or false-negative over a 7-month period. The study confirmed the value of this ELISA using protein A conjugate to detect antibodies directed against T. evansi in camels and the need to use several diagnostic techniques to optimize detection of infected animals. A warning is raised on surra, a potentially emerging disease in Europe.


Subject(s)
Antibodies, Protozoan/blood , Camelus , Disease Outbreaks/veterinary , Enzyme-Linked Immunosorbent Assay/veterinary , Trypanosomiasis/veterinary , Animals , Arsenicals/therapeutic use , Enzyme-Linked Immunosorbent Assay/methods , France/epidemiology , Polymerase Chain Reaction , Quinolinium Compounds/therapeutic use , Time Factors , Triazines/therapeutic use , Trypanocidal Agents/therapeutic use , Trypanosoma , Trypanosomiasis/blood , Trypanosomiasis/diagnosis , Trypanosomiasis/drug therapy , Trypanosomiasis/epidemiology
15.
Exp Neurol ; 215(2): 397-400, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18996373

ABSTRACT

Acridine-iminodibenzyl chimeric compounds were previously introduced as a class of cholesterol-redistributing substances with antiprion effects. Here, we show that administration of the lead compound quinpramine to mice with experimental autoimmune encephalitis, an animal model of multiple sclerosis (MS), significantly ameliorates disease in preventive and therapeutic paradigms. Quinpramine treatment decreased the number of inflammatory CNS lesions, antigen-specific T-cell proliferation, and pro-inflammatory cytokines IFNgamma and IL-17. Quinpramine is thus an immunoregulatory drug that is a candidate pharmaceutical for MS.


Subject(s)
Encephalomyelitis, Autoimmune, Experimental/drug therapy , Quinolinium Compounds/therapeutic use , Animals , Cell Proliferation/drug effects , Cytokines/metabolism , Disease Models, Animal , Encephalomyelitis, Autoimmune, Experimental/chemically induced , Female , Glycoproteins , Mice , Mice, Inbred C57BL , Myelin-Oligodendrocyte Glycoprotein , Peptide Fragments , T-Lymphocytes/drug effects
16.
Biomed Res ; 30(6): 365-8, 2009 Dec.
Article in English | MEDLINE | ID: mdl-20051646

ABSTRACT

In this study, we demonstrate that a cyanine dye, lumin, significantly suppressed cytopathic effect by herpes simplex virus (HSV)-1 toward human amnionic FL cell and also it reduced replication of HSV-1 in a dose-dependent manner. In addition, lumin additively augmented the antiviral effect of interferon (IFN)-alpha. Furthermore, fluorescence microscopic study showed that lumin (not IFN-alpha) itself remarkably induced alkalinization of intracellular organelle, suggesting the inhibition of virus invasion into the cells. These results suggest that lumin exerts an antiviral action against HSV-1 with the independent pathways of IFN-alpha and also it would become a therapeutically effective drug in clinical practice.


Subject(s)
Carbocyanines , Herpes Simplex/drug therapy , Herpesvirus 1, Human/drug effects , Quinolinium Compounds , Amniotic Fluid/cytology , Carbocyanines/pharmacology , Carbocyanines/therapeutic use , Cell Line , Endosomes/chemistry , Endosomes/drug effects , Humans , Hydrogen-Ion Concentration , Interferon-alpha/pharmacology , Interferon-alpha/therapeutic use , Quinolinium Compounds/pharmacology , Quinolinium Compounds/therapeutic use , Virus Replication/drug effects
17.
Curr Med Chem ; 15(13): 1305-15, 2008.
Article in English | MEDLINE | ID: mdl-18537610

ABSTRACT

Small conductance Ca(2+)-activated K(+) (SK(Ca)) channels comprise an important subclass of K(+) channels. Selective blockade of SK(Ca) channels may find application in the therapy of myotonic muscular dystrophy, gastrointestinal dysmotilities, memory disorders, narcolepsy, and alcohol abuse. In the cyclophanes described herein the two 4-aminoquinolinium groups are joined at the ring N atoms (linker L) and at the exocyclic N atoms (linker A). When both the spacer A and L have only one benzene ring, the blocking potency changes dramatically with simple structural variations in the linkers. One of these smaller cyclophanes having A = benzene-1,4-diylbis(methylene) and L = benzene-1,3-diylbis(methylene) shows activity in the low nanomolar range. Furthermore, the results with the present series add significantly to the structure-activity knowledge in the field, since they incorporate the first example of molecules in which the activity depends critically on the nature of the linkers joining the two quinolinium (Q) groups. Later on, a novel series of bis-quinolinium bis-alkylene cyclophanes was described. The biological results of the present series add support to the suggestion that the linkers of the two Q groups do not form direct interactions with the channel protein but comprise a molecular support for the two Q groups. Two important structural features of the pharmacophore for SK(Ca) channel blockade have been identified. These are (1) an optimum distance of ca. 5.8 A between the centroids of the pyridinium rings of the two quinolinium groups, and (2) a preference for conformations having the Q groups in a synperiplanar orientation.


Subject(s)
Alkanes/pharmacology , Apamin/pharmacology , Potassium Channel Blockers/pharmacology , Potassium Channels, Calcium-Activated/antagonists & inhibitors , Quinolinium Compounds/pharmacology , Alkanes/chemistry , Alkanes/metabolism , Alkanes/therapeutic use , Animals , Apamin/metabolism , Potassium Channel Blockers/chemistry , Potassium Channel Blockers/metabolism , Potassium Channel Blockers/therapeutic use , Potassium Channels, Calcium-Activated/metabolism , Quinolinium Compounds/chemistry , Quinolinium Compounds/metabolism , Quinolinium Compounds/therapeutic use , Substrate Specificity
18.
Vet Parasitol ; 154(3-4): 233-41, 2008 Jul 04.
Article in English | MEDLINE | ID: mdl-18450381

ABSTRACT

Horses kept for recreational riding purposes by a wildlife tourism company in a heavily tsetse fly-infested region of north-western Tanzania were systematically monitored to investigate the occurrence, presentation and management of tsetse-transmitted trypanosomosis. During a 23-month period, 18 clinical cases were diagnosed (Trypanosoma brucei or Trypanosoma congolense were identified) and treated and trypanosomes were implicated of involvement in four deaths. Pyrexia consistently aided early detection (17 cases). Ataxia, weight loss and anaemia were seen in chronic cases and conferred a poor prognosis. Delaying treatment by more than 2 days from the onset of clinical signs led to prolonged disease course and more severe anaemia. Early detection, prompt treatment, thorough post-treatment health monitoring and rigorous prophylactic measures helped keep clinical cases to manageable levels, but re-infection remained a constant, insidious threat.


Subject(s)
Animal Husbandry , Horse Diseases/prevention & control , Trypanosomiasis, African/veterinary , Animals , Horse Diseases/drug therapy , Horse Diseases/epidemiology , Horses , Phenanthridines/therapeutic use , Quinolinium Compounds/therapeutic use , Tanzania/epidemiology , Trypanocidal Agents/therapeutic use , Trypanosomiasis, African/drug therapy , Trypanosomiasis, African/epidemiology , Trypanosomiasis, African/prevention & control
19.
Apoptosis ; 13(6): 748-55, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18415680

ABSTRACT

Quinolines are a class of chemical compounds with emerging anti-cancer properties. Here, we tested the activity of series of quinolines and quinoline-like molecules for anti-cancer activity and identified a novel diquinoline, 1-methyl-2-[3-(1-methyl-1,2-dihydroquinolin-2-yliden)prop-1-enyl]quinolinium iodide (Q(2)). Q(2 )induced cell death in leukemia, myeloma, and solid tumor cell lines with LD50s in the low to submicromolar range. Moreover, Q(2) induced cell death in primary acute myeloid leukemia (AML) cells preferentially over normal hematopoietic cells. In a mouse model of leukemia, Q(2) delayed tumor growth. Mechanistically, Q(2) induced cell death through caspase independent mechanisms. By electron microscopy, Q(2) increased cytoplasmic vacuolization and mitochondrial swelling. Potentially consistent with the induction of autophagic cell death, Q(2) treatment led to a punctate distribution of LC3 and increased MDC staining. Thus, Q(2) is a novel quinolinium with preclinical activity in malignancies such as leukemia and myeloma and warrants further investigation.


Subject(s)
Cell Death/drug effects , Quinolinium Compounds/pharmacology , Amino Acid Chloromethyl Ketones/pharmacology , Animals , Autophagy/drug effects , Caspases/physiology , Cell Line, Tumor , Cell Survival/drug effects , HeLa Cells , Humans , Jurkat Cells , Lethal Dose 50 , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Leukemia, Myeloid, Acute/drug therapy , Mice , Mice, Inbred DBA , Quinolinium Compounds/therapeutic use , Tumor Cells, Cultured , U937 Cells
20.
Acta Trop ; 90(3): 271-5, 2004 May.
Article in English | MEDLINE | ID: mdl-15099814

ABSTRACT

In order to understand drug resistance in Chinese Trypanosoma evansi isolates, the in vitro growth inhibition test was carried out to detect the sensitivities to suramin and antrycide of 12 T. evansi isolates. For suramin, 50% inhibitory concentrations (IC(50)) ranged from 0.041 to 0.752 microg/ml; for antrycide, the IC(50) values ranged from 0.00151 to 0.06694 microg/ml. In vivo experiments in mice with selected isolates showed that the isolate most resistant to suramin was not cured at a dosage of 10 mg/kg, while the isolate that was most resistant to antrycide showed only 50% cure rate at a dose rate of 5 mg/kg. The data presented here indicate that T. evansi isolates from China had differences in drug resistance, with some isolates exhibiting low sensitivity to suramin or antrycide, while a few isolates showed complete drug resistance to curative dosages of suramin or antrycide. No drug cross-resistance was observed between suramin and antrycide.


Subject(s)
Drug Resistance , Quinolinium Compounds/pharmacology , Suramin/pharmacology , Trypanocidal Agents/pharmacology , Trypanosoma/drug effects , Animals , China/epidemiology , Disease Models, Animal , Female , Humans , Male , Mice , Parasitic Sensitivity Tests , Quinolinium Compounds/therapeutic use , Suramin/therapeutic use , Trypanocidal Agents/therapeutic use , Trypanosomiasis/epidemiology , Trypanosomiasis/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL